EICHORCondition: Leukemia · Sponsor: Thomas Helleday Foundation
The primary objective of this study is to determine safety and tolerability of Karonudib for the treatment of hematological malignancies. Secondary objectives are to determine a recommended RP2D and schedule for further development of Karonudib, to determine the pharmacokinetics of Karonudib, to look for evidence of treatment efficacy. Overall survival will also be recorded.
This description comes directly from the study's public registry record.
Maria Klockare, BSc · +46706232505 · maria.klockare@oxcia.com
Always discuss trial participation with your own doctor first.
| Aarhus University Hospital | Aarhus, Denmark | Recruiting |
| Rigshospitalet Copenhagen University Hospital | Copenhagen, Denmark | Recruiting |
| University Clinical Center Belgrade | Belgrade, Serbia | Recruiting |
| Vojnomedicinska akademija, Klinika za hematologiju | Belgrade, Serbia | Recruiting |
| University Clinical Center Kragujevac | Kragujevac, Serbia | Recruiting |
| Karolinska University Hospital | Huddinge, Sweden | Recruiting |
| Örebro University Hospital | Örebro, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04077307